{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T10:15:32Z","timestamp":1790158532938,"version":"4.1.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2018,7,21]],"date-time":"2018-07-21T00:00:00Z","timestamp":1532131200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2018,7,21]],"date-time":"2018-07-21T00:00:00Z","timestamp":1532131200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Forschungsgemeinschaft","award":["Sachbeihilfe PR 1405\/2-2, Heisenberg-Professur PR"],"award-info":[{"award-number":["Sachbeihilfe PR 1405\/2-2, Heisenberg-Professur PR"]}]},{"name":"Dr. Ralph and Marian Falk Medical Research Trust Bank of America, N.A., Trustee grant"},{"DOI":"10.13039\/501100012353","name":"German Cancer Consortium","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100012353","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Else-Kr\u00f6ner-Fresenius Foundation graduate college for Translational Research Innovation"},{"DOI":"10.13039\/100000135","name":"NIH Blueprint for Neuroscience Research","doi-asserted-by":"publisher","award":["DK103616"],"award-info":[{"award-number":["DK103616"]}],"id":[{"id":"10.13039\/100000135","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetologia"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1007\/s00125-018-4685-0","type":"journal-article","created":{"date-parts":[[2018,7,21]],"date-time":"2018-07-21T08:33:45Z","timestamp":1532162025000},"page":"2235-2246","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["A novel dual PPAR-\u03b3 agonist\/sEH inhibitor treats diabetic complications in a rat model of type 2 diabetes"],"prefix":"10.1007","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5940-9300","authenticated-orcid":false,"given":"Md Abdul","family":"Hye Khan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Kolb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Skibba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9","family":"Bl\u00f6cher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewgenij","family":"Proschak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D.","family":"Imig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,7,21]]},"reference":[{"key":"4685_CR1","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1177\/0884533609342436","volume":"24","author":"MV Potenza","year":"2009","unstructured":"Potenza MV, Mechanick JI (2009) The metabolic syndrome: definition, global impact, and pathophysiology. Nutr Clin Pract 24:560\u2013577","journal-title":"Nutr Clin Pract"},{"key":"4685_CR2","doi-asserted-by":"publisher","first-page":"683","DOI":"10.2337\/diacare.24.4.683","volume":"24","author":"B Isomaa","year":"2001","unstructured":"Isomaa B, Almgren P, Tuomi T et al (2001) Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 24:683\u2013689","journal-title":"Diabetes Care"},{"key":"4685_CR3","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/nrd2005","volume":"5","author":"SM Grundy","year":"2006","unstructured":"Grundy SM (2006) Drug therapy of the metabolic syndrome: minimizing the emerging crisis in polypharmacy. Nat Rev Drug Discov 5:295\u2013309","journal-title":"Nat Rev Drug Discov"},{"key":"4685_CR4","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1097\/FJC.0b013e3181e96e0c","volume":"56","author":"JD Imig","year":"2010","unstructured":"Imig JD (2010) Targeting epoxides for organ damage in hypertension. J Cardiovasc Pharmacol 56:329\u2013335","journal-title":"J Cardiovasc Pharmacol"},{"key":"4685_CR5","doi-asserted-by":"publisher","first-page":"9038","DOI":"10.1073\/pnas.1103482108","volume":"108","author":"A Luria","year":"2011","unstructured":"Luria A, Bettaieb A, Xi Y et al (2011) Soluble epoxide hydrolase deficiency alters pancreatic islet size and improves glucose homeostasis in a model of insulin resistance. Proc Natl Acad Sci U S A 108:9038\u20139043","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4685_CR6","doi-asserted-by":"publisher","first-page":"758614","DOI":"10.1155\/2012\/758614","volume":"2012","author":"A Iyer","year":"2012","unstructured":"Iyer A, Kauter K, Alam MA et al (2012) Pharmacological inhibition of soluble epoxide hydrolase ameliorates diet-induced metabolic syndrome in rats. Exp Diabetes Res 2012:758614","journal-title":"Exp Diabetes Res"},{"key":"4685_CR7","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.prostaglandins.2015.04.011","volume":"120","author":"C Roche","year":"2015","unstructured":"Roche C, Guerrot D, Harouki N et al (2015) Impact of soluble epoxide hydrolase inhibition on early kidney damage in hyperglycemic overweight mice. Prostaglandins Other Lipid Mediat 120:148\u2013154","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"4685_CR8","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s10557-014-6530-0","volume":"28","author":"MA Hye Khan","year":"2014","unstructured":"Hye Khan MA, Neck\u00e1\u0159 J, Cummens B, Wahl GM, Imig JD (2014) Azilsartan decreases renal and cardiovascular injury in the spontaneously hypertensive obese rat. Cardiovasc Drugs Ther 28:313\u2013322","journal-title":"Cardiovasc Drugs Ther"},{"key":"4685_CR9","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1017\/S0007114514004437","volume":"113","author":"E Molinar-Toribio","year":"2015","unstructured":"Molinar-Toribio E, P\u00e9rez-Jim\u00e9nez J, Ramos-Romero S et al (2015) Effect of n-3 PUFA supplementation at different EPA:DHA ratios on the spontaneously hypertensive obese rat model of the metabolic syndrome. Br J Nutr 113:878\u2013887","journal-title":"Br J Nutr"},{"key":"4685_CR10","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1046\/j.1523-1755.2002.00278.x","volume":"61","author":"SP Tofovic","year":"2002","unstructured":"Tofovic SP, Kost CK Jr, Jackson EK, Bastacky SI (2002) Long-term caffeine consumption exacerbates renal failure in obese, diabetic, ZSF1 (fa-facp) rats. Kidney Int 61:1433\u20131444","journal-title":"Kidney Int"},{"key":"4685_CR11","doi-asserted-by":"publisher","first-page":"2945","DOI":"10.1681\/ASN.2006080895","volume":"18","author":"S Prabhakar","year":"2007","unstructured":"Prabhakar S, Starnes J, Shi S, Lonis B, Tran R (2007) Diabetic nephropathy is associated with oxidative stress and decreased renal nitric oxide production. J Am Soc Nephrol 18:2945\u20132952","journal-title":"J Am Soc Nephrol"},{"key":"4685_CR12","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1021\/acs.jmedchem.5b01239","volume":"59","author":"R Bl\u00f6cher","year":"2016","unstructured":"Bl\u00f6cher R, Lamers C, Wittmann SK et al (2016) N-Benzylbenzamides: a novel merged scaffold for orally available dual soluble epoxide hydrolase\/peroxisome proliferator-activated receptor \u03b3 modulators. J Med Chem 59:61\u201381","journal-title":"J Med Chem"},{"key":"4685_CR13","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1258\/ebm.2012.012225","volume":"237","author":"JD Imig","year":"2012","unstructured":"Imig JD, Walsh KA, Hye Khan MA et al (2012) Soluble epoxide hydrolase inhibition and peroxisome proliferator activated receptor \u03b3 agonist improve vascular function and decrease renal injury in hypertensive obese rats. Exp Biol Med (Maywood) 237:1402\u20131412","journal-title":"Exp Biol Med (Maywood)"},{"key":"4685_CR14","doi-asserted-by":"publisher","first-page":"817","DOI":"10.2165\/00002512-200320110-00003","volume":"20","author":"V Rollason","year":"2003","unstructured":"Rollason V, Vogt N (2003) Reduction of polypharmacy in the elderly: a systematic review of the role of the pharmacist. Drugs Aging 20:817\u2013832","journal-title":"Drugs Aging"},{"key":"4685_CR15","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1002\/jcp.10294","volume":"196","author":"EJ Henriksen","year":"2003","unstructured":"Henriksen EJ, Jacob S (2003) Modulation of metabolic control by angiotensin converting enzyme (ACE) inhibition. J Cell Physiol 196:171\u2013179","journal-title":"J Cell Physiol"},{"key":"4685_CR16","unstructured":"Hunsicker LG (2004) Emerging trends for prevention and treatment of diabetic nephropathy: blockade of the RAAS and BP control. J Manag Care Pharm (5 Suppl A):S12\u2013S17"},{"key":"4685_CR17","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1038\/ki.2011.381","volume":"81","author":"D Batlle","year":"2012","unstructured":"Batlle D, Wysocki J, Soler MJ (2012) Angiotensin-converting enzyme 2: enhancing the degradation of angiotensin II as a potential therapy for diabetic nephropathy. Kidney Int 81:520\u2013528","journal-title":"Kidney Int"},{"key":"4685_CR18","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.amjhyper.2005.12.017","volume":"19","author":"PA Sarafidis","year":"2006","unstructured":"Sarafidis PA, Lasaridis AN (2006) Actions of peroxisome proliferator-activated receptors-gamma agonists explaining a possible blood pressure-lowering effect. Am J Hypertens 19:646\u2013653","journal-title":"Am J Hypertens"},{"key":"4685_CR19","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1097\/MNH.0b013e3282f9b1c0","volume":"17","author":"AB Fogo","year":"2008","unstructured":"Fogo AB (2008) Potential for peroxisome proliferator-activated receptor-gamma agonists in progression: beyond metabolism. Curr Opin Nephrol Hypertens 17:282\u2013285","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"4685_CR20","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1016\/S0140-6736(05)66378-7","volume":"365","author":"RH Eckel","year":"2005","unstructured":"Eckel RH, Grundy SM, Zimmet PZ (2005) The metabolic syndrome: epidemiology, mechanisms, and therapy. Lancet 365:1415\u20131428","journal-title":"Lancet"},{"key":"4685_CR21","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1038\/sj.ijo.0802943","volume":"29","author":"MC Carmona","year":"2005","unstructured":"Carmona MC, Louche K, Nibbelink M et al (2005) Fenofibrate prevents rosiglitazone-induced body weight gain in ob\/ob mice. Int J Obes 29:864\u2013871","journal-title":"Int J Obes"},{"key":"4685_CR22","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1517\/14740331003623218","volume":"9","author":"P Shah","year":"2010","unstructured":"Shah P, Mudaliar S (2010) Pioglitazone: side effect and safety profile. Expert Opin Drug Saf 9:347\u2013354","journal-title":"Expert Opin Drug Saf"},{"key":"4685_CR23","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1038\/nm1278","volume":"11","author":"Y Guan","year":"2005","unstructured":"Guan Y, Hao C, Cha DR et al (2005) Thiazolidinediones expand body fluid volume through PPAR\u03b3 stimulation of ENaC-mediated renal salt absorption. Nat Med 11:861\u2013866","journal-title":"Nat Med"},{"key":"4685_CR24","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1042\/CS20130479","volume":"127","author":"MA Hye Khan","year":"2014","unstructured":"Hye Khan MA, Pavlov TS, Christain SV et al (2014) Epoxyeicosatrienoic acid analogue lowers blood pressure through vasodilation and sodium channel inhibition. Clin Sci (Lond) 127:463\u2013474","journal-title":"Clin Sci (Lond)"},{"key":"4685_CR25","doi-asserted-by":"publisher","first-page":"F672","DOI":"10.1152\/ajprenal.00597.2010","volume":"301","author":"TS Pavlov","year":"2011","unstructured":"Pavlov TS, Ilatovskaya DV, Levchenko V (2011) Effects of cytochrome P-450 metabolites of arachidonic acid on the epithelial sodium channel (ENaC). Am J Physiol Ren Physiol 301:F672\u2013F681","journal-title":"Am J Physiol Ren Physiol"},{"key":"4685_CR26","doi-asserted-by":"publisher","first-page":"5223","DOI":"10.1074\/jbc.M112.407981","volume":"288","author":"N Pidkovka","year":"2013","unstructured":"Pidkovka N, Rao R, Mei S et al (2013) Epoxyeicosatrienoic acids (EETs) regulate epithelial sodium channel activity by extracellular signal-regulated kinase 1\/2 (ERK1\/2)-mediated phosphorylation. J Biol Chem 288:5223\u20135231","journal-title":"J Biol Chem"},{"key":"4685_CR27","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.2337\/dc12-2258","volume":"36","author":"S Stark Casagrande","year":"2013","unstructured":"Stark Casagrande S, Fradkin JE, Saydah SH, Rust KF, Cowie CC (2013) The prevalence of meeting A1C, blood pressure, and LDL goals among people with diabetes, 1988-2010. Diabetes Care 36:2271\u20132279","journal-title":"Diabetes Care"},{"key":"4685_CR28","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.1001\/jama.2011.861","volume":"305","author":"IH de Boer","year":"2011","unstructured":"de Boer IH, Rue TC, Hall YN, Heagerty PJ, Weiss NS, Himmelfarb J (2011) Temporal trends in the prevalence of diabetic kidney disease in the United States. JAMA 305:2532\u20132539","journal-title":"JAMA"},{"key":"4685_CR29","doi-asserted-by":"publisher","first-page":"2864","DOI":"10.2337\/dc14-1296","volume":"37","author":"KR Tuttle","year":"2014","unstructured":"Tuttle KR, Bakris GL, Bilous RW et al (2014) Diabetic kidney disease: a report from an ADA Consensus Conference. Diabetes Care 37:2864\u20132883","journal-title":"Diabetes Care"},{"key":"4685_CR30","doi-asserted-by":"publisher","first-page":"4394","DOI":"10.1016\/j.bmcl.2016.07.079","volume":"26","author":"J Brenneman","year":"2016","unstructured":"Brenneman J, Hill J, Pullen S (2016) Emerging therapeutics for the treatment of diabetic nephropathy. Bioorg Med Chem Lett 26:4394\u20134402","journal-title":"Bioorg Med Chem Lett"},{"key":"4685_CR31","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.dsx.2016.06.005","volume":"10","author":"S John","year":"2016","unstructured":"John S (2016) Complication in diabetic nephropathy. Diabetes Metab Syndr 10:247\u2013249","journal-title":"Diabetes Metab Syndr"},{"key":"4685_CR32","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/nrendo.2010.212","volume":"7","author":"DK Singh","year":"2011","unstructured":"Singh DK, Winocour P, Farrington K (2011) Oxidative stress in early diabetic nephropathy: fueling the fire. Nat Rev Endocrinol 7:176\u2013184","journal-title":"Nat Rev Endocrinol"},{"key":"4685_CR33","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1038\/ncpendmet0894","volume":"4","author":"S Dronavalli","year":"2008","unstructured":"Dronavalli S, Duka I, Bakris GL (2008) The pathogenesis of diabetic nephropathy. Nat Clin Pract Endocrinol Metab 4:444\u2013452","journal-title":"Nat Clin Pract Endocrinol Metab"},{"key":"4685_CR34","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/ncpendmet0046","volume":"1","author":"PH Groop","year":"2005","unstructured":"Groop PH, Forsblom C, Thomas MC (2005) Mechanisms of disease: pathway-selective insulin resistance and microvascular complications of diabetes. Nat Clin Pract Endocrinol Metab 1:100\u2013110","journal-title":"Nat Clin Pract Endocrinol Metab"},{"key":"4685_CR35","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.cmet.2014.08.005","volume":"20","author":"RE Soccio","year":"2014","unstructured":"Soccio RE, Chen ER, Lazar MA (2014) Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes. Cell Metab 20:573\u2013591","journal-title":"Cell Metab"},{"key":"4685_CR36","first-page":"1882","volume":"85","author":"JR Petrie","year":"2000","unstructured":"Petrie JR, Morris AD, Ueda S et al (2000) Trandolapril does not improve insulin sensitivity in patients with hypertension and type 2 diabetes: a double-blind, placebo-controlled crossover trial. J Clin Endocrinol Metab 85:1882\u20131889","journal-title":"J Clin Endocrinol Metab"},{"key":"4685_CR37","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1055\/s-2007-978766","volume":"31","author":"T Heise","year":"1999","unstructured":"Heise T, Heinemann L, Kristahn K et al (1999) Insulin sensitivity in patients with essential hypertension: no influence of the ACE inhibitor enalapril. Horm Metab Res 31:418\u2013423","journal-title":"Horm Metab Res"},{"key":"4685_CR38","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1530\/JOE-11-0122","volume":"210","author":"VP Bilan","year":"2011","unstructured":"Bilan VP, Salah EM, Bastacky S et al (2011) Diabetic nephropathy and long-term treatment effects of rosiglitazone and enalapril in obese ZSF1 rats. J Endocrinol 210:293\u2013308","journal-title":"J Endocrinol"},{"key":"4685_CR39","doi-asserted-by":"publisher","first-page":"30","DOI":"10.2337\/diaspect.21.1.30","volume":"21","author":"S Steigerwalt","year":"2008","unstructured":"Steigerwalt S (2008) Management of hypertension in diabetic patients with chronic kidney disease. Diabetes Spectrum 21:30\u201336","journal-title":"Diabetes Spectrum"},{"key":"4685_CR40","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s11906-015-0601-x","volume":"17","author":"M Stump","year":"2015","unstructured":"Stump M, Mukohda M, Hu C, Sigmund CD (2015) PPAR\u03b3 regulation in hypertension and metabolic syndrome. Curr Hypertens Rep 17:89","journal-title":"Curr Hypertens Rep"},{"key":"4685_CR41","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1046\/j.1523-1755.2000.00165.x","volume":"58","author":"P Muntner","year":"2000","unstructured":"Muntner P, Coresh J, Smith JC, Eckfeldt J, Klag MJ (2000) Plasma lipids and risk of developing renal dysfunction: the atherosclerosis risk in communities study. Kidney Int 58:293\u2013301","journal-title":"Kidney Int"},{"key":"4685_CR42","doi-asserted-by":"publisher","first-page":"S87","DOI":"10.1111\/j.1523-1755.2005.09916.x","volume":"99","author":"A Cases","year":"2005","unstructured":"Cases A, Coll E (2005) Dyslipidemia and the progression of renal disease in chronic renal failure patients. Kidney Int Suppl 99:S87\u2013S93","journal-title":"Kidney Int Suppl"},{"key":"4685_CR43","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1161\/ATVBAHA.109.186064","volume":"29","author":"LN Zhang","year":"2009","unstructured":"Zhang LN, Vincelette J, Cheng Y et al (2009) Inhibition of soluble epoxide hydrolase attenuated atherosclerosis, abdominal aortic aneurysm formation, and dyslipidemia. Arterioscler Thromb Vasc Biol 29:1265\u20131270","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"4685_CR44","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1111\/1753-0407.12358","volume":"8","author":"J He","year":"2016","unstructured":"He J, Wang C, Zhu Y, Ai D (2016) Soluble epoxide hydrolase: a potential target for metabolic diseases. J Diabetes 8:305\u2013313","journal-title":"J Diabetes"},{"key":"4685_CR45","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1038\/nature05485","volume":"444","author":"GS Hotamisligil","year":"2006","unstructured":"Hotamisligil GS (2006) Inflammation and metabolic disorders. Nature 444:860\u2013867","journal-title":"Nature"},{"key":"4685_CR46","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1016\/j.juro.2015.08.105","volume":"195","author":"S Ma","year":"2016","unstructured":"Ma S, Zhu XY, Eirin A et al (2016) Perirenal fat promotes renal arterial endothelial dysfunction in obese swine 508 through tumor necrosis factor-alpha. J Urol 195:1152\u20131259","journal-title":"J Urol"},{"key":"4685_CR47","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1124\/jpet.111.191247","volume":"341","author":"Y Liu","year":"2012","unstructured":"Liu Y, Webb HK, Fukushima H et al (2012) Attenuation of cisplatin-induced renal injury by inhibition of soluble epoxide hydrolase involves nuclear factor \u03baB signaling. J Pharmacol Exp Ther 341:725\u2013734","journal-title":"J Pharmacol Exp Ther"},{"key":"4685_CR48","doi-asserted-by":"publisher","first-page":"F131","DOI":"10.1152\/ajprenal.00531.2014","volume":"308","author":"J Kim","year":"2015","unstructured":"Kim J, Yoon SP, Toews ML et al (2015) Pharmacological inhibition of soluble epoxide hydrolase prevents renal interstitial fibrogenesis in obstructive nephropathy. Am J Physiol Ren Physiol 308:F131\u2013F139","journal-title":"Am J Physiol Ren Physiol"},{"key":"4685_CR49","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1093\/ndt\/gfl194","volume":"21","author":"S Lee","year":"2006","unstructured":"Lee S, Kim W, Moon SO et al (2006) Rosiglitazone ameliorates cisplatin-induced renal injury in mice. Nephrol Dial Transplant 21:2096\u20132105","journal-title":"Nephrol Dial Transplant"},{"key":"4685_CR50","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/labinvest.2008.104","volume":"89","author":"T Kawai","year":"2009","unstructured":"Kawai T, Masaki T, Doi S et al (2009) PPAR-\u03b3 agonist attenuates renal interstitial fibrosis and inflammation through reduction of TGF-\u03b2. Lab Investig 89:47\u201358","journal-title":"Lab Investig"},{"key":"4685_CR51","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1055\/s-0028-1091986","volume":"28","author":"N Rafiq","year":"2008","unstructured":"Rafiq N, Younossi ZM (2008) Effects of weight loss on nonalcoholic fatty liver disease. Semin. Liver Dis 28:427\u2013433","journal-title":"Semin. Liver Dis"},{"key":"4685_CR52","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1053\/j.gastro.2014.11.039","volume":"148","author":"RJ Wong","year":"2015","unstructured":"Wong RJ, Aguilar M, Cheung R et al (2015) Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology 148:547\u2013555","journal-title":"Gastroenterology"},{"key":"4685_CR53","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/nrgastro.2016.147","volume":"14","author":"H Tilg","year":"2017","unstructured":"Tilg H, Moschen AR, Roden M (2017) NAFLD and diabetes mellitus. Nat Rev Gastroenterol Hepatol 14:32\u201342","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"4685_CR54","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1002\/hep.28785","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi ZM, Blissett D, Blissett R et al (2016) The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe. Hepatology 64:1577\u20131586","journal-title":"Hepatology"},{"key":"4685_CR55","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1097\/00000441-200110000-00016","volume":"322","author":"A Schattner","year":"2001","unstructured":"Schattner A, Kozak N, Friedman J (2001) Captopril-induced jaundice: report of 2 cases and a review of 13 additional reports in the literature. Am J Med Sci 322:236\u2013240","journal-title":"Am J Med Sci"},{"key":"4685_CR56","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1093\/ajh\/hpt090","volume":"26","author":"A Douros","year":"2013","unstructured":"Douros A, Kauffmann W, Bronder E, Klimpel A, Garbe E (2013) Kreutz R (2013) Ramipril-induced liver injury: case report and review of the literature. Am J Hypertens 26:1070\u20131075","journal-title":"Am J Hypertens"},{"key":"4685_CR57","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.5858\/2003-127-1493-RH","volume":"127","author":"E Yeung","year":"2003","unstructured":"Yeung E, Wong FS, Wanless IR et al (2003) Ramipril-associated hepatotoxicity. Arch Pathol Lab Med 127:1493\u20131497","journal-title":"Arch Pathol Lab Med"},{"key":"4685_CR58","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.bbrc.2005.08.070","volume":"336","author":"M Inoue","year":"2005","unstructured":"Inoue M, Ohtake T, Motomura W et al (2005) Increased expression of PPAR\u03b3 in high fat diet-induced liver steatosis in mice. Biochem Biophys Res Commun 336:215\u2013222","journal-title":"Biochem Biophys Res Commun"},{"key":"4685_CR59","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1210\/jc.2010-2129","volume":"96","author":"P Pettinelli","year":"2011","unstructured":"Pettinelli P, Videla LA (2011) Up-regulation of PPAR-\u03b3 mRNA expression in the liver of obese patients: an additional reinforcing lipogenic mechanism to SREBP-1c induction. J Clin Endocrinol Metab 96:1424\u20131430","journal-title":"J Clin Endocrinol Metab"},{"key":"4685_CR60","doi-asserted-by":"publisher","first-page":"e39165","DOI":"10.1371\/journal.pone.0039165","volume":"7","author":"Y Liu","year":"2012","unstructured":"Liu Y, Dang H, Li D, Pang W, Hammock BD, Zhu Y (2012) Inhibition of soluble epoxide hydrolase attenuates high-fat-diet\u2013induced hepatic steatosis by reduced systemic inflammatory status in mice. PLoS One 7:e39165","journal-title":"PLoS One"},{"key":"4685_CR61","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.taap.2015.03.022","volume":"286","author":"TR Harris","year":"2015","unstructured":"Harris TR, Bettaieb A, Kodani S et al (2015) Inhibition of soluble epoxide hydrolase attenuates hepatic fibrosis and endoplasmic reticulum stress induced by carbon tetrachloride in mice. Toxicol Appl Pharmacol 286:102\u2013111","journal-title":"Toxicol Appl Pharmacol"},{"key":"4685_CR62","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1111\/hepr.12856","volume":"47","author":"Y Sumida","year":"2016","unstructured":"Sumida Y, Seko Y, Yoneda M (2016) Japan Study Group of NAFLD (JSG-NAFLD). Novel antidiabetic medications for nonalcoholic fatty liver disease with type 2 diabetes. Hepatol Res 47:266\u2013280","journal-title":"Hepatol Res"},{"key":"4685_CR63","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.ejphar.2012.04.028","volume":"685","author":"G Qiang","year":"2012","unstructured":"Qiang G, Zhang L, Yang X et al (2012) Effect of valsartan on the pathological progression of hepatic fibrosis in rats with type 2 diabetes. Eur J Pharmacol 685:156\u2013164","journal-title":"Eur J Pharmacol"}],"container-title":["Diabetologia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00125-018-4685-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-018-4685-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-018-4685-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,28]],"date-time":"2022-08-28T01:06:34Z","timestamp":1661648794000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00125-018-4685-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,21]]},"references-count":63,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["4685"],"URL":"https:\/\/doi.org\/10.1007\/s00125-018-4685-0","relation":{},"ISSN":["0012-186X","1432-0428"],"issn-type":[{"value":"0012-186X","type":"print"},{"value":"1432-0428","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,21]]},"assertion":[{"value":"21 March 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"JDI, EP, MAHK and RB have a patent application that covers the composition of matter for RB394. All other authors declare that there is no duality of interest associated with their contribution to this article.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Duality of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}